BTK Inhibitors in CLL/SLL: The Landscape 10 Years Out

Abstract:

The BTK-targeting arsenal for chronic lymphocytic leukemia or small lymphocytic lymphoma continues to expand, with a noncovalent inhibitor, pirtobrutinib, now an approved later-line option. As well, a fourth-generation candidate, LP-168, which is both irreversible/reversible, has shown preliminary phase I efficacy. BTK inhibitors have limited utility on their own, however; to combat resistance and achieve durable remissions, the field is looking toward multidrug combinations, including with potentially disease-eradicating CAR T-cell therapy.